Telomir Pharmaceuticals has entered into a consulting agreement with Andriy Mushak to serve as fractional chief financial officer effective June 6, 2026, providing senior financial leadership for SEC compliance, audit readiness, and capital markets support. The engagement strengthens the company's financial infrastructure and governance capabilities as it advances regulatory and growth objectives.